Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma.

Arnold JM, Huggard PR, Cummings M, Ramm GA, Chenevix-Trench G

The Queensland Institute of Medical Research, c/o RBH Post Office, Herston, Brisbane, QLD 4029, Australia. jeremyA@qimr.edu.au

Chemokine (C-C motif) ligand-2 (CCL2) is a chemoattractant and activator of macrophages and is a key determinant of the macrophage infiltrate into tumours. We demonstrate here that CCL2 is expressed in normal human ovarian surface epithelium (HOSE) cells and is silenced in most ovarian cancer cell lines, and silenced or downregulated in the majority of primary ovarian adenocarcinomas. Analysis of the CCL2 locus at 17q11.2-q12 showed loss of heterozygosity (LOH) in 70% of primary tumours, and this was significantly more common in tumours of advanced stage or grade. However, we did not detect any mutations in the CCL2 coding sequence in 94 primary ovarian adenocarcinomas. These data support the hypothesis that CCL2 may play a role in the pathobiology of ovarian cancers, but additional studies will be required to evaluate this possibility.

Published 1 June 2005 in Br J Cancer, 92(11): 2024-31.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.